Zhi Tong Cai Jing·2026-02-24 14:31Core Viewpoint - Eli Lilly (LLY.US) shares fell over 1.5% in pre-market trading following news that competitor Novo Nordisk (NVO.US) will reduce the official prices of its GLP-1 drugs in the U.S. market [1] Group 1: Price Reduction Announcement - Novo Nordisk announced a price reduction for its GLP-1 drugs, including Wegovy, Ozempic, and Rybelsus, effective January 1, 2027 [1] - The price adjustment will lower the wholesale acquisition cost of Wegovy and Ozempic by approximately 35% to 50%, applying to both injectable and oral forms [1] - The new monthly price for Wegovy and Ozempic will be standardized to $675 [1] Group 2: Market Context and Implications - Despite the price reduction, Novo Nordisk's market performance in the lucrative anti-obesity drug sector remains behind that of Eli Lilly [1] - The company stated that the price reduction aims to enhance affordability for patients and public/private payers in the evolving U.S. healthcare system [1] - The price adjustment is expected to particularly benefit patients whose out-of-pocket costs are linked to official pricing, although it will not affect Novo Nordisk's direct-to-consumer pricing structure [2]